3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
63
Colorectal Neoplasms
30
Biliary Tract Neoplasms
29
Cholangiocarcinoma
27
Pancreatic Neoplasms
26
Liver Neoplasms
18
Stomach Neoplasms
13
Esophageal Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
8
Ovarian Neoplasms
7
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Carcinoma, Renal Cell
6
Carcinoma
6
Bile Duct Neoplasms
6
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Prostatic Neoplasms
5
Colonic Neoplasms
5
Uterine Cervical Neoplasms
4
Lung Neoplasms
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Adenocarcinoma
4
Neoplasms
3
Interventions
Gemcitabine
3
pembrolizumab
2
napabucasin
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
linifanib
1
durvalumab
1
dabrafenib
1
copper dotatate CU-64
1
cobimetinib
1
capmatinib
1
atezolizumab
1
Vemurafenib
1
Pemetrexed
1
Paclitaxel
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Immunotherapy
1
HhAntag691
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
durvalumab
×
Gastrointestinal
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled